Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Toshikazu Ushijima is active.

Publication


Featured researches published by Toshikazu Ushijima.


Gastroenterology | 2012

Inflammation-Associated Cancer Development in Digestive Organs: Mechanisms and Roles for Genetic and Epigenetic Modulation

Tsutomu Chiba; Hiroyuki Marusawa; Toshikazu Ushijima

Chronic inflammation, regardless of infectious agents, plays important roles in the development of various cancers, particularly in digestive organs, including Helicobacter pylori-associated gastric cancer, hepatitis C virus-positive hepatocellular carcinoma, and colitis-associated colon cancers. Cancer development is characterized by stepwise accumulation of genetic and epigenetic alterations of various proto-oncogenes and tumor-suppressor genes. During chronic inflammation, infectious agents such as H pylori and hepatitis C virus as well as intrinsic mediators of inflammatory responses, including proinflammatory cytokines and reactive oxygen and nitrogen species, can induce genetic and epigenetic changes, including point mutations, deletions, duplications, recombinations, and methylation of various tumor-related genes through various mechanisms. Furthermore, inflammation also modulates the expressions of microRNAs that influence the production of several tumor-related messenger RNAs or proteins. These molecular events induced by chronic inflammation work in concert to alter important pathways involved in normal cellular function, and hence accelerate inflammation-associated cancer development. Among these, recent studies highlighted an important role of activation-induced cytidine deaminase, a nucleotide-editing enzyme essential for somatic hypermutation and class-switch recombination of the immunoglobulin gene, as a genomic modulator in inflammation-associated cancer development.


Nature | 2008

Moving AHEAD with an international human epigenome project

Peter A. Jones; Trevor K. Archer; Stephen B. Baylin; Stephan Beck; Shelley L. Berger; Bradley E. Bernstein; John D. Carpten; Susan J. Clark; Joseph F. Costello; R. W. Doerge; Manel Esteller; Andrew P. Feinberg; Thomas R. Gingeras; John M. Greally; Steven Henikoff; James G. Herman; Laurie Jackson-Grusby; Thomas Jenuwein; Randy L. Jirtle; Young-Joon Kim; Peter W. Laird; Bing Lim; Robert A. Martienssen; Kornelia Polyak; Henk Stunnenberg; Thea D. Tlsty; Benjamin Tycko; Toshikazu Ushijima; Jingde Zhu; Vincenzo Pirrotta

A plan to genomicize epigenomics research and pave the way for breakthroughs in the prevention, diagnosis and treatment of human disease.


Trends in Neurosciences | 2015

Epigenetic Mechanisms of Chronic Pain

Giannina Descalzi; Daigo Ikegami; Toshikazu Ushijima; Eric J. Nestler; Venetia Zachariou; Minoru Narita

Neuropathic and inflammatory pain promote a large number of persisting adaptations at the cellular and molecular level, allowing even transient tissue or nerve damage to elicit changes in cells that contribute to the development of chronic pain and associated symptoms. There is evidence that injury-induced changes in chromatin structure drive stable changes in gene expression and neural function, which may cause several symptoms, including allodynia, hyperalgesia, anxiety, and depression. Recent findings on epigenetic changes in the spinal cord and brain during chronic pain may guide fundamental advances in new treatments. Here, we provide a brief overview of epigenetic regulation in the nervous system and then discuss the still-limited literature that directly implicates epigenetic modifications in chronic pain syndromes.


International Journal of Cancer | 2014

Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer

Takeichi Yoshida; Jun Kato; Izumi Inoue; Noriko Yoshimura; Hisanobu Deguchi; Chizu Mukoubayashi; Masashi Oka; Mika Watanabe; Shotaro Enomoto; Toru Niwa; Takao Maekita; Mikitaka Iguchi; Hideyuki Tamai; Hirotoshi Utsunomiya; Nobutake Yamamichi; Mitsuhiro Fujishiro; Masataka Iwane; Tatsuya Takeshita; Toshikazu Ushijima; Masao Ichinose

Our study investigated the relationship between gastric cancer development and activity of Helicobacter pylori‐associated chronic gastritis or the resulting chronic atrophic gastritis (CAG). A cohort of 4,655 healthy asymptomatic subjects, in whom serum pepsinogen (PG) and H. pylori antibody titer had been measured to assess the activity and stage of H. pylori‐associated chronic gastritis, was followed for up to 16 years, and cancer development was investigated. In subjects with a serologically diagnosed healthy stomach (H. pylori‐negative/CAG‐negative), cancer incidence rate was low, at 16/100,000 person‐years. With the establishment of H. pylori infection and progression of chronic gastritis, significant stepwise cancer risk elevations were seen from CAG‐free subjects (H. pylori‐positive/CAG‐negative) [hazard ratio (HR)u2009=u20098.9, 95% confidence interval (CI)u2009=u20092.7–54.7] to subjects with CAG (H. pylori‐positive/CAG‐positive) (HRu2009=u200917.7, 95% CIu2009=u20095.4–108.6) and finally to subjects with metaplastic gastritis (H. pylori‐negative/CAG‐positive) (HRu2009=u200969.7, 95% CIu2009=u200913.6–502.9). In H. pylori‐infected CAG‐free subjects, significantly elevated cancer risk was observed in the subgroup with active inflammation‐based high PG II level or potent immune response‐based high H. pylori antibody titer; the former was associated with a particularly high risk of diffuse‐type cancer, and both subgroups showed high cancer incidence rates of around 250/100,000 person‐years, comparable to that in subjects with CAG. No such risk elevation was observed in H. pylori‐infected subjects with CAG. These results clearly indicate that gastric cancer develops mainly from the gastritis‐atrophy‐metaplasia‐cancer sequence and partly from active inflammation‐based direct carcinogenesis, and that serum levels of PG and H. pylori antibody titer provide indices of cancer development in H. pylori‐infected subjects.


Cytogenetic and Genome Research | 2006

Applying whole-genome studies of epigenetic regulation to study human disease

Jason D. Lieb; Stephan Beck; Martha L. Bulyk; Peggy J. Farnham; Naka Hattori; Steven Henikoff; Xiaole Shirley Liu; Katsuzumi Okumura; Kunio Shiota; Toshikazu Ushijima; John M. Greally

Epigenetics may be broadly defined as the study of processes that produce a heritable phenotype that is not strictly dependent on DNA sequence. The definition has traditionally been restricted to processes that occur in the cells nucleus, with the term “heritable” having a loose meaning that can be applied to either the entire organism or single cells. For example, a process that produces a phenotype only in a specific cell type (for instance, chromatin-mediated maintenance of a differentiated state) is usually considered epigenetic even if it is not directly inherited, but instead must be reestablished or actively maintained at each cell division. Given this definition, the field of epigenetics has long focused on proteins that affect DNA packaging, and thereby affect the utilization of the genetic information encoded in the DNA template. This focus extends to the enzymatic modification of those proteins, and to the enzymatic modification of the DNA template itself, primarily DNA methylation. n nThis review is written in conjunction with the international symposium on Genome-wide Epigenetics 2005, held at the University of Tokyo, Japan on November 8–10, 2005. Over the past decade, the field of epigenetics has undergone an exciting expansion in the number of researchers, techniques available and our understanding of epigenetic phenomena. The purpose of this short review is not to summarize all of these advances, but rather to guide the reader to more detailed sources of information by sketching an outline of the major thrusts in the field, emphasizing mammalian epigenetics in particular.


Development | 2013

Dose-dependent roles for canonical Wnt signalling in de novo crypt formation and cell cycle properties of the colonic epithelium.

Akihiro Hirata; Jochen Utikal; Satoshi Yamashita; Hitomi Aoki; Akira Watanabe; Takuya Yamamoto; Hideyuki Okano; Nabeel Bardeesy; Takahiro Kunisada; Toshikazu Ushijima; Akira Hara; Rudolf Jaenisch; Yasuhiro Yamada

There is a gradient of β-catenin expression along the colonic crypt axis with the highest levels at the crypt bottom. In addition, colorectal cancers show a heterogeneous subcellular pattern of β-catenin accumulation. However, it remains unclear whether different levels of Wnt signalling exert distinct roles in the colonic epithelium. Here, we investigated the dose-dependent effect of canonical Wnt activation on colonic epithelial differentiation by controlling the expression levels of stabilised β-catenin using a doxycycline-inducible transgenic system in mice. We show that elevated levels of Wnt signalling induce the amplification of Lgr5+ cells, which is accompanied by crypt fission and a reduction in cell proliferation among progenitor cells. By contrast, lower levels of β-catenin induction enhance cell proliferation rates of epithelial progenitors without affecting crypt fission rates. Notably, slow-cycling cells produced by β-catenin activation exhibit activation of Notch signalling. Consistent with the interpretation that the combination of Notch and Wnt signalling maintains crypt cells in a low proliferative state, the treatment of β-catenin-expressing mice with a Notch inhibitor turned such slow-cycling cells into actively proliferating cells. Our results indicate that the activation of the canonical Wnt signalling pathway is sufficient for de novo crypt formation, and suggest that different levels of canonical Wnt activations, in cooperation with Notch signalling, establish a hierarchy of slower-cycling stem cells and faster-cycling progenitor cells characteristic for the colonic epithelium.


Neuropathology and Applied Neurobiology | 2016

Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas

Taishi Nakamura; Kensuke Tateishi; T. Niwa; Y. Matsushita; Kaoru Tamura; Manabu Kinoshita; Kazuhiro Tanaka; S. Fukushima; H. Takami; Hideyuki Arita; A. Kubo; T. Shuto; Makoto Ohno; Yasuji Miyakita; Sylvia Kocialkowski; Takashi Sasayama; Naoya Hashimoto; Taketoshi Maehara; Soichiro Shibui; Toshikazu Ushijima; Nobutaka Kawahara; Yoshitaka Narita; Koichi Ichimura

Primary central nervous system lymphoma (PCNSL) manifest aggressive clinical behaviour and have poor prognosis. Although constitutive activation of the nuclear factor‐κB (NF‐κB) pathway has been documented, knowledge about the genetic alterations leading to the impairment of the NF‐κB pathway in PCNSLs is still limited. This study was aimed to unravel the underlying genetic profiles of PCNSL.


Cancer Letters | 2013

Comprehensive DNA methylation and extensive mutation analyses reveal an association between the CpG island methylator phenotype and oncogenic mutations in gastric cancers

Jeong Goo Kim; Hideyuki Takeshima; Tohru Niwa; Emil Rehnberg; Yasuyuki Shigematsu; Yukie Yoda; Satoshi Yamashita; Ryoji Kushima; Takao Maekita; Masao Ichinose; Hitoshi Katai; Won Sang Park; Young Seon Hong; Cho Hyun Park; Toshikazu Ushijima

Recent development of personal sequencers for extensive mutation analysis and bead array technology for comprehensive DNA methylation analysis have made it possible to obtain integrated pictures of genetic and epigenetic alterations on the same set of cancer samples. Here, we aimed to establish such pictures of gastric cancers (GCs). Comprehensive methylation analysis of 30 GCs revealed that the number of aberrantly methylated genes was highly variable among individual GCs. Extensive mutation analysis of 55 known cancer-related genes revealed that 19 of the 30 GCs had 24 somatic mutations of eight different genes (CDH1, CTNNB1, ERBB2, KRAS, MLH1, PIK3CA, SMARCB1, and TP53). Integration of information on the genetic and epigenetic alterations revealed that the GCs with the CpG island methylator phenotype (CIMP) tended to have mutations of oncogenes, CTNNB1, ERBB2, KRAS, and PIK3CA. This is one of the first studies in which both genetic and epigenetic alterations were extensively analyzed in the same set of samples. It was also demonstrated for the first time in GCs that the CIMP was associated with oncogene mutations.


Cancer Letters | 2013

Interleukin-1β induced by Helicobacter pylori infection enhances mouse gastric carcinogenesis.

Yasuyuki Shigematsu; Tohru Niwa; Emil Rehnberg; Takeshi Toyoda; Satoshi Yoshida; Akiko Mori; Mika Wakabayashi; Yoichiro Iwakura; Masao Ichinose; Yongjoon Kim; Toshikazu Ushijima

Interleukin-1β (Il1b) is considered to be involved in Helicobacter pylori (HP)-induced human gastric carcinogenesis, while the role of its polymorphisms in gastric cancer susceptibility remains controversial. Here, we aimed to clarify the role of HP infection-induced IL1B in gastric inflammation and carcinogenesis using Il1b(-/-) (Il1b-null) mice. In gastric mucosa of the Il1b(+/+) (WT) mice, HP infection induced Il1b expression and severe inflammation. In contrast, in Il1b-null mice, recruitment of neutrophils and macrophages by HP infection was markedly suppressed. In a carcinogenicity test, the multiplicity of gastric tumors was significantly suppressed in theIl1b-null mice (58% of WT; P<0.005). Mechanistically, HP infection induced NF-κB activation both in the inflammatory and epithelial cells in gastric mucosae, and the activation was attenuated in the Il1b-null mice. Accordingly, increased proliferation and decreased apoptosis of gastric epithelial cells induced by HP infection in the WT mice were attenuated in the Il1b-null mice. These results demonstrated that the IL1B physiologically induced by HP infection enhanced gastric carcinogenesis by affecting both inflammatory and epithelial cells.


The Journal of Pathology | 2016

Frequent PTPRK-RSPO3 fusions and RNF43 mutations in colorectal traditional serrated adenoma.

Shigeki Sekine; Satoshi Yamashita; Taro Tanabe; Taiki Hashimoto; Hiroshi Yoshida; Hirokazu Taniguchi; Motohiro Kojima; Kazuya Shinmura; Yutaka Saito; Nobuyoshi Hiraoka; Toshikazu Ushijima; Atsushi Ochiai

The molecular mechanisms underlying the serrated pathway of colorectal tumourigenesis, particularly those related to traditional serrated adenomas (TSAs), are still poorly understood. In this study, we analysed genetic alterations in 188 colorectal polyps, including hyperplastic polyps, sessile serrated adenomas/polyps (SSA/Ps), TSAs, tubular adenomas, and tubulovillous adenomas by using targeted next‐generation sequencing and reverse transcription‐PCR. Our analyses showed that most TSAs (71%) contained genetic alterations in WNT pathway components. In particular, PTPRK–RSPO3 fusions (31%) and RNF43 mutations (24%) were frequently and almost exclusively observed in TSAs. Consistent with the WNT pathway activation, immunohistochemical analysis showed diffuse and focal nuclear accumulation of β‐catenin in 53% and 30% of TSAs, respectively. APC mutations were observed in tubular and tubulovillous adenomas and in a subset of TSAs. BRAF mutations were exclusively and frequently encountered in serrated lesions. KRAS mutations were observed in all types of polyps, but were most commonly encountered in tubulovillous adenomas and TSAs. This study has demonstrated that TSAs frequently harbour genetic alterations that lead to WNT pathway activation, in addition to BRAF and KRAS mutations. In particular, PTPRK–RSPO3 fusions and RNF43 mutations were found to be characteristic genetic features of TSAs. Copyright

Collaboration


Dive into the Toshikazu Ushijima's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Takao Maekita

Wakayama Medical University

View shared research outputs
Researchain Logo
Decentralizing Knowledge